1. Scrip
  2. >>Focus On Asia
  3. >>China

China’s Duyiwei Biological Acquires Two Hospitals, One More Soon

Gansu Duyiwei Biological Pharmaceutical Co. Ltd. plans to acquire Pengxi TCM Hospital, according to the company secretary, which follows two other purchases that include Deyang Better Future Hospital Co. Ltd. at RMB 25 million ($4 million) and Ziyang Jianshunwang Check-up Hospital Co. Ltd. for RMB 40 million.

Gansu Duyiwei Biological Pharmaceutical Co. Ltd.plans to acquire Pengxi TCM Hospital, according to the company secretary, which follows two other purchases that include Deyang Better Future Hospital Co. Ltd. at RMB 25 million ($4 million) and Ziyang Jianshunwang Check-up Hospital Co. Ltd. for RMB 40 million. The acquisitions, all via Duyiwei’s wholly-owned subsidiary Sichuan Lybrand Medical Investment Management Co. Ltd., came with compensated annual net profit guarantees for 2013-15 of RMB 6-7 million for Ziyang, and RMB 4-5 million for Deyang. (Click Here For More - Chinese Language

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 
• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

China Deal-Making Matures As Foreign Partners Derisk Asset Acquisition

 
• By Xu Hu

Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.

Vocal For ‘Glocal’: How Menarini Is Adapting To Outperform In The Asia Pacific

 
• By Anju Ghangurde

Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.

More from Focus On Asia

China Deal-Making Matures As Foreign Partners Derisk Asset Acquisition

 
• By Xu Hu

Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.

Vocal For ‘Glocal’: How Menarini Is Adapting To Outperform In The Asia Pacific

 
• By Anju Ghangurde

Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.